- The P-III PREPARE study involves assessing ResVax vs PBO in 4,636 pregnant women to prevent the risk of RSV Disease in infants
- PREPARE study results: didn’t met 1EPs @prevention of medically significant RSV LRTI; 39% against medically significant RSV LRTI; 44% against RSV LRTI hospitalizations; 48% against RSV LRTI with severe hypoxemia; reduction in LRTI hospitalizations & hypoxemia (25% & 39%); vaccine efficacy against RSV LRTI hospitalization & hypoxemia@< 33wks. pregnancy (53%,70% vs 26%,44%)
- ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine used in combination with aluminum phosphate for prevention of severe LRTI in infants >1yrs.
Click here to read full press release/ article | Ref: Novavax | Image: Getty images